SCHEMBL6129273

SCHEMBL6129273

CO/C(=C\c1ccccc1)C(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.51
TSHR P16473 1/20 0.50
AKR1C1 Q04828 1/20 0.50
CES2 O00748 4/20 0.48
CES1 P23141 4/20 0.48
MTNR1A P48039 2/20 0.47
MTNR1B P49286 2/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
AKR1C3 P42330 1/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL728021 1.00 ABCG2 (0.51) ABCG2TSHRAKR1C1CES2CES1
SCHEMBL9207327 0.85 ALDH1A1 (0.45) ABCG2CES2CES1MEN1KMT2A
SCHEMBL83065 0.84 AKR1C3 (0.55) ABCG2TSHRAKR1C1MEN1KMT2A
SCHEMBL3818255 0.84 AKR1C3 (0.55) ABCG2TSHRAKR1C1MEN1KMT2A
SCHEMBL3485765 0.84 AKR1C3 (0.55) ABCG2TSHRAKR1C1MEN1KMT2A
SCHEMBL9103420 0.84 ABCG2 (0.54) ABCG2TSHRAKR1C1MTNR1AMTNR1B
SCHEMBL5047540 0.82 RECQL (0.55) ABCG2TSHRMTNR1AMTNR1BMEN1
Hydrochloric Acid SCHEMBL10437231 0.82 AKR1C3 (0.53) ABCG2TSHRAKR1C1MEN1KMT2A
SCHEMBL1397476 0.82 ABCG2 (0.53) ABCG2TSHRMEN1KMT2AMAPT
SCHEMBL8351839 0.82 AKR1C3 (0.53) ABCG2TSHRAKR1C1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050065213-A1 Combretastatin a-4 derivatives having antineoplastic activity LAWRENCE NICHOLAS JAMES (GB) 2005-03-24 US disclosed
US-4014896-A Catalytic dehydrogenation process for the preparation of 3,4,5-trisubstituted pyrazoles AMERICAN CYANAMID COMPANY (US) 1977-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065213-A1 Combretastatin a-4 derivatives having antineoplastic activity AURKA, AURKB, HDAC4 ABCG2 33/4885TSHR 4276/4885AKR1C1 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.